MTR 0.00% $3.95 mantra group limited

Cancer trials great success, page-2

  1. 2,070 Posts.
    A low-toxicity cancer drug is a big deal no? Especially from a small company.

    MEDITECH RESEARCH LIMITED 2002-06-27 ASX-SIGNAL-G

    HOMEX - Perth

    +++++++++++++++++++++++++
    PHASE I TRIALS OF MEDITECH'S HyACT(TM) ANTI-CANCER DRUG HyDOX(TM)
    INDICATES A SAFE AND EFFICACIOUS NEW GENERATION ANTI-CANCER TREATMENT

    Meditech Research Limited has completed analysis of the data generated by the Phase I human clinical trials of its anti-cancer drug HyDOX(TM) and is pleased to report that the trial was an unqualified success. The purpose of the trial was to demonstrate that use of Meditech's patented HyACT(TM) technology in combination with the well-established anti-cancer drug doxorubicin (HyDOX(TM) is safe for use in humans.

    The HyD0X(TM) anti-cancer product was trialled in patients with several types of cancer including Breast, Kidney, Prostate and Gastric cancer. Analysis of the HyDOX(TM) trial data confirmed that the Meditech product is safe for use in treatment of cancer. Analysis
    of the data also highlighted very encouraging indications of tumour response to the therapy.

    In pre-clinical studies, use of Meditech's HyACT(TM) formulation with doxorubicin produced a significant reduction in side effects such as heart damage, bone marrow suppression and severe gastro intestinal problems. Such side effects are the major limitation in both the dosage and duration of administration of widely used chemotherapy anti-cancer drugs such as doxorubicin.

    Meditech believes future human clinical trials will confirm results of HyACT(TM) tests in animals which demonstrate that the technology not only reduces side effects, but also improves the effectiveness of a variety of the most important therapeutically active anti-cancer agents, many of which are the primary chemotherapy products already in use in cancer clinics. Effectiveness of the HyACT(TM) technology is achieved through the selective targeting of potent anti-cancer drugs directly to tumours where it then makes the cancer cells more sensitive to the drug resulting in greater tumour killing.

    Meditech Research Limited is confident that if efficacy, as well as safety can be statistically confirmed in future human clinical trials of HyDOX(TM), the HyACT(TM) technology will also be safe and effective in formulations with many other anti-cancer agents which belong to the large cytotoxic drug market (annual sales in 1999: US$7billion(1). Meditech is now designing Phase II clinical trial protocols with an expectation of starting these trials in the later months of 2002.

    (1) Market summary of Cytotoxics Data Monitor May 2001

    FOR FURTHER INFORMATION, CONTACT:

    Meditech: http://www.mrl.com.au
    Professor Richard Fox: (03) 9342 7695
    Dr Tracey Brown: (03) 9905 3760
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.